Last $2.88 USD
Change Today -0.05 / -1.71%
Volume 436.5K
ONTY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

oncothyreon inc (ONTY) Snapshot

Open
$2.93
Previous Close
$2.93
Day High
$3.00
Day Low
$2.79
52 Week High
03/13/14 - $4.08
52 Week Low
06/28/13 - $1.55
Market Cap
203.7M
Average Volume 10 Days
735.7K
EPS TTM
$-0.66
Shares Outstanding
70.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOTHYREON INC (ONTY)

oncothyreon inc (ONTY) Related Businessweek News

No Related Businessweek News Found

oncothyreon inc (ONTY) Details

Oncothyreon Inc, a clinical-stage biopharmaceutical company, develops therapeutic products for the treatment of cancer. Its product candidate includes Tecemotide, a vaccine for the treatment of non-small cell lung cancer. The company is also developing ONT-10, a cancer vaccine, which is in Phase I clinical trial for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate cancers, as well as various lung cancer; ONT-380, a small-molecule HER2 inhibitor that is in Phase Ib trial for the treatment of metastatic breast cancer, including patients with brain metastases; and PX-866, which has completed two Phase II trials for the treatment of various cancers. In addition, it develops PET lipid-A, a proprietary synthetic lipid-A analog. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

43 Employees
Last Reported Date: 03/13/14
Founded in 1985

oncothyreon inc (ONTY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $422.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $267.8K
Chief Operating Officer
Total Annual Compensation: $300.8K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $345.1K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: $262.7K
Compensation as of Fiscal Year 2013.

oncothyreon inc (ONTY) Key Developments

Oncothyreon Inc Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Cash Flow Guidance for the Year 2014

Oncothyreon Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported loss from operations of $7,583,000 compared to $6,970,000 a year ago. Net loss was $6,363,000 or $0.09 diluted per share compared to net income of $4,254,000 or $0.12 diluted per share a year ago. The increase in loss from operations was primarily due to slight increases in general and administrative expenses and research and development expenses. The net loss for the quarter ended December 31, 2013 compared to the net income in the comparable prior year period was primarily attributable to the difference in the change in the fair value of warrant liability. For the year, the company reported loss from operations of $41,223,000 compared to $28,499,000 a year ago. Net loss was $38,759,000 or $0.62 diluted per share compared to $3,415,000 or $0.53 diluted per share a year ago. The increase in loss from operations resulted primarily from an increase in research and development expenses to $33.2 million from $22.0 million, which included a $10.0 million upfront payment to Array BioPharma Inc. (Array) upon execution of the collaboration agreement with Array in May 2013. The increase in net loss was primarily attributable to the difference in the change in the fair value of warrant liability, with $2.3 million in non-cash income for the year ended December 31, 2013, compared with $25.5 million in non-cash income for the prior year. The company currently expects cash used in operations in 2014 to be approximately $30 million to $33 million.

Oncothyreon Inc to Report Q4, 2013 Results on Mar 13, 2014

Oncothyreon Inc announced that they will report Q4, 2013 results on Mar 13, 2014

Oncothyreon Inc, Q4 2013 Earnings Call, Mar 13, 2014

Oncothyreon Inc, Q4 2013 Earnings Call, Mar 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTY:US $2.88 USD -0.05

ONTY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTY.
View Industry Companies
 

Industry Analysis

ONTY

Industry Average

Valuation ONTY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOTHYREON INC, please visit www.oncothyreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.